In a new study, researchers from Zhejiang University, the Chinese Academy of Sciences, and Xiamen University have developed a novel approach to combat cancerous tumors. The method, named ONCOTECH, combines oncolytic virusRead More…
Cancer is an increasingly severe global public health issue, with an urgent need for new anticancer drugs. Recent studies have identified oncolytic viruses as a relatively new class of cancer immunotherapy. OncolyticRead More…
Glioblastoma (GBM) is an aggressive brain cancer known for its resistance to treatment, with patients experiencing recurrent GBM having a survival period of less than 10 months. Immunotherapy, which mobilizes the body’sRead More…
Immunotherapy has garnered significant attention due to its potential in achieving long-term control of tumor progression and extending the survival of patients in cancer treatment. Dendritic cells (DCs), known as the mostRead More…
Oncolytic viruses (OVs) are a promising treatment for solid tumors. When injected into tumors, oncolytic viruses are able to selectively target cancer cells without affecting normal cells, causing cancer cell lysis byRead More…
Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases. Compared with other types of breast cancer, TNBC is more likely to spread, metastasize, and recur, and as itRead More…
City of Hope, a world-renowned research and treatment organization for cancer, diabetes, and other life-threatening diseases, recently announced the initiation of a first-in-human clinical trial evaluating the use of an anti-cancer oncolyticRead More…
Oncolytic viruses (OVs) have emerged as a very attractive cancer treatment modality. OVs target cancer cells without affecting normal cells, causing cancer cell lysis by replicating within cancer cells and, at theRead More…
As early as around 1800, doctors discovered that certain cancer patients would have their symptoms eased after being briefly infected with some viruses. Although the concept of using viruses to treat cancerRead More…